Why Amarin Is Tanking After Hours

Amarin (NASDAQ: AMRN  ) is plunging more than 20% in after-hours trading, after disclosing that it will be hiring a sales force for its flagship drug Vascepa. Investors were hoping for a swift buyout, and tonight's late-breaking announcement may be a blow to that happening. Management insisted that all options are still on the table ahead of a potential NCE status update next week, but this is still widely seen as a blow to a buyout or partnership. Watch health-care analysts David Williamson and Max Macaluso discuss where this leaves Amarin investors in the following video.

Today's events are an easy reminder that the biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of its new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top analyst Max Macaluso's premium research report. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (4)

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2143383, ~/Articles/ArticleHandler.aspx, 8/30/2016 12:59:06 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 hours ago Sponsored by:
DOW 18,502.99 107.59 0.58%
S&P 500 2,180.38 11.34 0.52%
NASD 5,232.33 13.41 0.26%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/29/2016 4:02 PM
AET $117.02 Down -0.21 -0.18%
Aetna CAPS Rating: ***
AMRN $2.99 Down -0.09 -2.92%
Amarin CAPS Rating: ****
GSK $43.61 Up +0.06 +0.14%
GlaxoSmithKline CAPS Rating: ***
VVUS $1.09 Up +0.03 +2.83%
VIVUS CAPS Rating: **